Neurocrine Biosciences, Inc. (NBIX)
155.64
-2.71
(-1.71%)
USD |
NASDAQ |
Sep 04, 16:00
156.18
+0.54
(+0.35%)
After-Hours: 20:00
Neurocrine Biosciences SG&A Expense (TTM) : 1.352B for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.352B |
| March 31, 2026 | 1.198B |
| December 31, 2025 | 1.156B |
| September 30, 2025 | 1.142B |
| June 30, 2025 | 1.085B |
| March 31, 2025 | 1.041B |
| December 31, 2024 | 1.007B |
| September 30, 2024 | 938.30M |
| June 30, 2024 | 908.20M |
| March 31, 2024 | 888.00M |
| December 31, 2023 | 887.60M |
| September 30, 2023 | 851.60M |
| June 30, 2023 | 833.70M |
| March 31, 2023 | 794.70M |
| December 31, 2022 | 752.70M |
| September 30, 2022 | 726.30M |
| June 30, 2022 | 694.60M |
| March 31, 2022 | 655.00M |
| December 31, 2021 | 583.30M |
| September 30, 2021 | 533.30M |
| June 30, 2021 | 491.20M |
| March 31, 2021 | 444.50M |
| December 31, 2020 | 433.30M |
| September 30, 2020 | 428.10M |
| June 30, 2020 | 400.09M |
| Date | Value |
|---|---|
| March 31, 2020 | 384.41M |
| December 31, 2019 | 354.15M |
| September 30, 2019 | 321.83M |
| June 30, 2019 | 297.74M |
| March 31, 2019 | 277.83M |
| December 31, 2018 | 248.93M |
| September 30, 2018 | 236.26M |
| June 30, 2018 | 219.73M |
| March 31, 2018 | 200.49M |
| December 31, 2017 | 169.91M |
| September 30, 2017 | 137.26M |
| June 30, 2017 | 110.89M |
| March 31, 2017 | 84.18M |
| December 31, 2016 | 68.08M |
| September 30, 2016 | 53.35M |
| June 30, 2016 | 47.31M |
| March 31, 2016 | 38.95M |
| December 31, 2015 | 32.48M |
| September 30, 2015 | 28.51M |
| June 30, 2015 | 21.72M |
| March 31, 2015 | 19.32M |
| December 31, 2014 | 17.99M |
| September 30, 2014 | 16.36M |
| June 30, 2014 | 14.94M |
| March 31, 2014 | 14.11M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Amarin Corp. Plc | 76.76M |
| Liquidia Corp. | 192.66M |
| Halozyme Therapeutics, Inc. | 238.00M |
| Iovance Biotherapeutics, Inc. | 149.18M |
| Precigen, Inc. | 84.93M |